← Oncology Approval Tracker

FDA DECISION ·

Inluriyo

imlunestrant · Eli Lilly and Company

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on at least one endocrine therapy line.

LAMPGEN ANALYSIS

Why it matters

An oral estrogen receptor antagonist gives a biomarker-directed option after endocrine therapy in ESR1-mutated disease.

What research teams should watch

Arrange validated ESR1 testing at progression and verify prior endocrine exposure before changing treatment.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

ESR1-selected advanced or metastatic disease

PRIMARY RECORDS

Sources